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Abstract
Background
Crohn’s disease (CD) is a pathologic condition with different clinical expressions that may
reflect an interplay between genetics and environmental factors. Recently, it has been
highlighted that three genetic markers, NOD2, MHC and MST1, were associated to distinct
CD sites, supporting the concept that genetic variations may contribute to localize CD.
Genetic markers, previously shown to be associated with inflammatory bowel disease
(IBD), were tested in CD patients with the aim to better dissect the genetic relationship
between ileal, ileocolonic and colonic CD and ascertain whether a different genetic back-
ground would support the three disease sites as independent entities.
Methods
A panel of 29 SNPs of 19 IBD loci were analyzed by TaqMan SNP allelic discrimination
method both evaluating their distinct contribute and analyzing all markers jointly.
Results
Seven hundred and eight CD patients and 537 healthy controls were included in the study.
Of the overall population of patients, 237 patients had an ileal involvement (L1), 171 a
colonic localization (L2), and the 300 remaining an ileocolon location (L3). We confirmed the
association for 23 of 29 variations (P < 0.05). Compared to healthy controls, 16 variations
emerged as associated to an ileum disease, 7 with a colonic disease and 14 with an ileo-
colonic site (P < 0.05). Comparing ileum to colonic CD, 5 SNPs (17%) were differentially
associated (P < 0.05). A genetic model score that aggregated the risks of 23 SNPs and
their odds ratios (ORs), yielded an Area Under the Curve (AUC) of 0.70 for the overall CD
patients. By analyzing each CD location, the AUC remained at the same level for the ileal
and ileocolonic sites (0.73 and 0.72, respectively), but dropped to a 0,66 value in patients
with colon localization.
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Conclusions
Our findings reaffirm the existence of at least three different subgroups of CD patients, with
a genetic signature distinctive for the three main CD sites.
Introduction
Crohn’s disease (CD) is a pathologic condition with different clinical expressions that may
likely reflect a peculiar interplay between genetics and the environmental factors [1,2].
To date, more than 180 genes or loci have been associated with the susceptibility to CD [3–
5]. Of these, 138 loci conferred the risk to both CD and ulcerative colitis (UC), whereas 42
were unique to CD, albeit each variant had a small individual effect. Major established deter-
minants of the clinical course of CD are disease location, clinical behavior, age at disease onset,
and extra intestinal manifestations [6–13]. While disease behavior and extraintestinal manifes-
tation dramatically change over the course of CD, disease sites shows little or no variation [14]
and might serve as a clue to define distinct entities of CD. Recently, Cleynen I. et al [15]
highlighted three genetic markers (16q12/NOD2, 6p21/MHC and 3p21/MST1) associated to
distinct CD sites, supporting the concept that peculiar genetic pathways may contribute to
localize CD. From the genetic analysis, colonic CD had peculiar loci different from those
expressed in either ileal CD and UC. Albeit the prospect to use genetic markers in refining the
molecular classification of CD has been extensively evaluated, only the association between
NOD2 variants and ileal CD has been validated unambiguously [16].
In the present work we tested a panel of 29 SNPs of 19 loci previously shown to be associ-
ated with disease sites of inflammatory bowel disease (IBD) to better dissect the genetic rela-
tionship between ileal, ileocolonic and colonic Crohn’s disease and ascertain whether a
different genetic background would support the three disease sites as independent entities
both evaluating their distinct contribute and analyzing all markers jointly.
Subjects and Methods
Patients
Seven hundreds and 8 CD cases were recruited at gastroenterologic and paediatric referral cen-
tres in the framework of the IBD genetic study, a multi-centre collaborative effort started in
1998 and co-ordinated by the Division of Gastroenterology of the IRCCS, ‘Casa Sollievo della
Sofferenza’, Hospital, Italy. 403 DNA samples from CD patients were shared with the Interna-
tional IBD Genetic Consortium projects, and were also included in our previously works. 537
healthy blood donors without personal or familial history of inflammatory disorders were also
included in the study. Patients’ feature and clinical data were stored in an anonymized data-
base. The study and the experimental protocols received the approval from the ethic commit-
tee of the ‘Casa Sollievo della Sofferenza’ Hospital (N. 12701/08) and were performed in
accordance with declaration of Helsinki approved guidelines. All participants had signed an
informed consent form before study entry.
Diagnosis of CD was based on the Lennard Jones criteria [17]. According to Montreal’s
classification [9] disease confined exclusively to the distal ileum, with or without cecum
involvement, was labeled as L1, exclusively to the colon as L2, and as L3 in the event of an ile-
colonic location. Disease located in the upper digestive tract was labeled as L4.
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Genotyping
DNA was extracted from peripheral blood using the Qiagen DNA Blood Kit procedure (Qia-
gen, Hilden, Germany). All patients and controls were genotyped for 29 Single Nucleotide
Polymorphisms (SNPs) of 19 loci, using TaqMan SNP allelic discrimination method by means
of an AB17900HT sequence detection system (Applied Biosystems Inc., Foster City, CA) at
“Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy.
The list of the investigated SNPs was obtained by screening of the available literature by two
investigators (OP, AL). 26 CD-related SNPs encompassing 18 genomic loci from fine mapping
or GWAs studies, were selected (S1 Table). Finally, we selected three variations among those
identified by Cleynen et colleagues [15] encompassing the HLA locus: the SNPs rs6930777 and
rs9268832, the SNP rs9267798 was typed instead of the rs4151651 being in Linkage Disequilib-
rium with the former (D’ = 0.82 and r2 = 0.62 in CEU population) (S1 Table).
Statistical analyses
Univariate and multivariate stepwise logistic regressions were performed using SPSS software
version 14.0 (SPSS, Chicago, IL, USA) and Haploview Software version 4.1 (http://www.broad.
mit.edu/personal/mpg/haploview). The allelic frequencies for all investigated polymorphisms
were tested for consistency with the Hardy-Weinberg equilibrium. Allelic and genotypic asso-
ciations of SNPs were evaluated by Pearson’s χ2 test (or Fisher’s test whenever appropriate).
Compared to the control group, Odds ratio and 95% confidence intervals (CI) were estimated
for each disease site (ileal, ileocolonic and colonic).
The stepwise logistic regression model was applied for all the variations significantly associ-
ated to the trait after correcting for multiple comparisons. This approach allowed to take into
account a dose-response effect (heterozygote or homozygote), and the possible interactions
between genes. P-values of less than 0.05 and 2.6e-3 after Bonferroni correction for multiple
testing were considered significant.
In addition, to estimate the predictive value of multiple susceptibility loci on the disease sta-
tus, we constructed a Genetic Risk Score (GRS) based on significant SNPs in the case-control
study (P < 0.05) and their respectively odds ratios. We assigned to each subject a score based
on the number of risk alleles carried for the SNPs associated with CD risk. We named “0” the
common allele homozygote carriers, “1” the heterozygotes, and “2” the rare allele homozy-
gotes. The number of risk alleles at each locus (2, 1, 0) was multiplied by their corresponding
beta-coefficients of effect sizes [log(OR)] and then summed up in GRS that each individual
carried. For the ORs we used “positive” scores achieved by the CD and healthy controls
cohorts [18]. The receiving operating characteristic (ROC) curve was used to measure the area
under the curve (AUC), sensitivity and specificity at various GRS cut-off.
Results
Case–control study
The allele frequencies of the SNPs analyzed were in accordance with the predicted Hardy-
Weinberg equilibrium in all subgroups of CD (ileal CD, ileocolonic CD and colonic CD)
(P> 0.05). Clinical and demographic characteristics of CD patients their initial presentation
are shown in Table 1.
Association between polymorphisms and CD
The allele frequencies of the 29 SNPs analyzed were compared between CD patients and con-
trols, and the results are reported in Table 2. We confirmed the association for 23 of the 26
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selected variations associated to CD, while none of three SNPs located in the HLA region was
significantly associated with CD. The most significant associations were observed for the varia-
tions rs2066844 [P = 1.0e-5, OR 2.1 (1.5–1.3)], rs2066845 [P = 9.0e-8, OR 4.0 (2.3–6.9)], and
rs2066847 [P = 1.4e-6, OR 2.9 (1.8–4.6)] in the NOD2 gene, rs7517847 [P = 4.2e-7, OR 0.6 (0.5–
0.8)] in IL23R gene, and rs1000113 [P = 4.3e-6, OR 1.7 (1.4–2.2)] in the IRGM gene.
Significant associations were achieved for the SNPs rs4263839 [P = 1.0e-5, OR 1.5 (1.3–1.8)]
located in TNFSF15 gene and for the SNP rs2413583 [P = 7.0e-5, OR 1.5 (1.2–1.9)] near the
MAP3K7IP1 gene. The SNPs located in loci encompassing the genes IL10, GCRK and TAGAP
didn’t reach the nominal statistical significance.
Table 1. Clinical and demographic characteristics of CD patients at initial presentation. Data are shown either for the entire cohort of patients and sep-
arately for disease sites.
All Disease sites
n = 708 ileum (L1) ileo-colon (L3) colon (L2)
n = 237 n = 300 n = 171
n % n % n % n %
GENDER
female 294 42 88 37 120 40 86 50
male 414 58 149 63 180 60 85 50
Age at diagnosis (years)
mean±sd; 30±14 32±14 28±13 32±15
Age decades (years)
 16 115 16 29 12 60 20 26 15
17-40 442 63 150 63 186 62 106 62
> 40 151 21 58 25 54 18 39 23
Smoking
yes 218 31 76 32 95 32 47 27
no 366 53 114 48 156 52 96 56
ex 108 16 38 16 43 14 27 16
missing 16 9 6 1
Behavoiur
B1 537 76 164 69 224 75 149 87
B2 102 14 47 20 44 15 11 6
B3 69 10 26 11 32 10 11 6
Familiar CD
yes 66 10 24 10 29 10 13 8
no 627 90 208 90 267 90 152 92
missing 15 5 4 6
Surgical presentation
yes 88 13 41 18 37 13 10 6
no 574 87 186 82 238 87 150 94
missing 46 10 25 11
Perianal disease
yes 15 2 4 2 8 3 3 2
no 683 98 229 98 290 97 164 98
missing 10 4 2 4
Colocation in upper digestive site
yes 47 7 17 7 25 8 5 3
no 661 93 220 93 275 92 166 97
doi:10.1371/journal.pone.0168821.t001
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Ileum localization
When compared to healthy controls, 16 variations of the 29 analyzed SNPs (55%) emerged as
associated to a disease localized to the ileum (P< 0.05) (Table 3). All these variants were
referred to 12 loci. The NOD2 and MAP3K7IP1 genes, belonging to the innate immunity
pathway, showed the strongest association. Carriers of the risk genotypes (aa + Aa) of the three
NOD2 polymorphisms showed a highly statistical significance: rs2066844 [P = 1.4e-6, OR 2.8
(1.8–4.3)], rs2066845 [P = 1.2e-5, OR 3.8 (2.0–7.1)], and rs2066847 [P = 6.5e-7, OR 3.7 (2.1–
6.4)]. At the univariate analysis, the presence of at least one of the NOD2 variants conferred a
high risk for a disease confined to the ileum [P = 9.6e-15, OR 3.8 (2.7–5.3)]. Similarly, carriers
of the variations rs1000113 and rs4958847 in the IRGM gene and of the rs713875 polymor-
phism of the MTMR3 gene, were at an increased risk for ileal CD: [P = 6.0e-5, OR 2.0 (1.5–
2.9)], [P = 0.005, OR 1.6 (1.1–2.2)] and [P = 0.003, OR 1.8 (1.2–2.7)], respectively. All the
remaining SNPs conferred the risk to an ileal localization. In particular, markers on the 3p21
locus named rs9858542 (BSN) and rs3197999 (MST1) manifested the highest association:
[P = 0.003, OR 1.6 (1.1–2.4)], and [P = 0.02, OR 1.5 (1.1–2.1)], respectively. Some variants had
Table 2. Allelic analysis in Crohn’s disease patients compared with healthy controls. * SNP associated after Bonferroni correction.
Chr = Chromosome; SNP = single nucleotide polymorphism; RAF = Risk Allele Frequencies; OR = Odd Ratio; CI = confidence interval
RAF
Chr SNP KEY GENE CASE,CONTROL P values OR IC 95%
1p31.3 rs7517847 IL23R 0.72, 0.62 * 4.16E-07 0.6 0.5-0.8
1p31.3 rs11209026 IL23R 0.96, 0.93 4.95E-03 0.6 0.4-0.9
1p36.23 rs2797685 PER3 0.23, 0.19 7.30E-03 1.3 1.1-1.6
1q32.1 rs3024505 IL10 0.16, 0.14 0.13576 - -
2p21 rs10495903 THADA 0.13, 0.10 2.39E-02 1.4 1.1-1.7
2p23.3 rs780093 GCKR 0.54, 0.53 0.53107 - -
2q37.1 rs2241880 ATG16L1 0.59, 0.53 6.85E-03 1.3 1.1-1.5
3p21.31 rs9858542 BSN 0.38, 0.30 6.17E-03 1.3 1.1-1.6
3p21.31 rs3197999 MST1 0.34, 0.29 2.16E-02 1.2 1.2-1.5
5q31 rs2631367 SLC22A4 0.46, 0.41 3.89E-02 1.2 1.0-1.4
5q31 rs1050152 SLC22A5 0.52, 0.47 2.04E-02 1.2 1.0-1.4
5q31 rs11739135 IGR2198 0.44, 0.40 3.56E-02 1.2 1.0-1.4
5q31 rs1521868 IGR2196 0.46, 0.39 * 2.12E-03 1.3 1.1-1.5
5q33.1 rs1000113 IRGM 0.18, 0.11 * 4.30E-06 1.7 1.4-2.2
5q33.1 rs4958847 IRGM 0.22, 0.17 * 9.30E-04 1.4 1.2-1.8
6p21 rs9268832 MHC 0.77, 0.73 0.17819 - -
6p21 rs6930777 MHC 0.93, 0.92 0.90981 - -
6p21 rs9267798 MHC 0.07, 0.07 0.95427 - -
6q25.3 rs212388 TAGAP 0.42, 0.41 0.52571 - -
9q32 rs4263839 TNFSF15 0.76, 0.68 * 1.00E-05 0.7 0.5-0.8
10q21.2 rs10761659 ZNF365 0.55, 0.47 * 8.40E-04 1.3 1.1-1.6
10q22.3 rs150550 ZMIZ1 0.79, 0.75 2.58E-02 0.8 0.7-1.0
10q24.2 rs11190140 NKX2/3 0.57, 0.51 3.58E-03 0.8 0.7-0.9
16q12.1 rs2066844 NOD2 0.09, 0.04 * 1.00E-05 2.1 1.5-3.0
16q12.1 rs2066845 NOD2 0.06, 0.01 * 9.01E-08 3.8 2.3-6.9
16q12.1 rs2066847 NOD2 0.06, 0.02 * 1.37E-06 2.9 2.9-4.6
18p11.21 rs2542151 PTPN2 0.16, 0.12 8.41E-03 1.4 1.1-1.8
22q12.2 rs713875 MTMR3 0.54, 0.48 5.43E-03 1.3 1.1-1.5
22q13.1 rs2413583 MAP3K7IP1 0.84, 0.77 * 7.00E-05 0.7 0.5-0.8
doi:10.1371/journal.pone.0168821.t002
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Table 3. Genotype analysis in ileal Crohn’s disease, colonic Crohn’s disease and ileocolonic Crohn’s disease patients. * SNP associated after Bon-
ferroni corrections. SNP = single nucleotide polymorphism; OR = Odd Ratio; CI = confidence interval.
ileum vs
control
Colon vs
control
ileocolon vs
control
Ileum vs
colon
ileocolon vs
colon
ileocolon vs
ileum
P value P value P value P value P value P value
SNP KEY GENE OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
rs7517847 IL23R * 1.3E-03 4.8E-03 4.8E-03
0.4 (0.2-0.7) 0.4 (0.2-0.8) 0.5 (0.3-0.8)
rs11209026 IL23R 3.1E-03
0.5 (0.3-0.8)
rs2797685 PER3 2.1E-02
1.5 (1.1-2.0)
rs10495903 THADA 2.5E-02 3.8E-02
1.5 (1.1-2.2) 1.4 (1.0-2.1)
rs2241880 ATG16L1 1.1E-02 1.3E-02
1.7 (1.1-2.6) 1.6 (1.1-2.3)
rs9858542 BSN * 2.6E-03 2.2E-02
1.7 (1.2-2.4) 1.6 (1.1-2.3)
rs3197999 MST1 1.9E-02 7.5E-03
1.5 (1.1-2.1) 1.7 (1.1-2.4)
rs2631367 SLC22A4 1.8E-02
1.6 (1.1-2.4)
rs1000113 IRGM * 6.0E-05 2.8E-02 * 2.3E-06
2.0 (1.4-2.9) 1.6 (1.1-2.3) 2.2 (1.6-3.0)
rs4958847 IRGM 5.3E-03 * 9.8E-04
1.6 (1.1-2.2) 1.7 (1.2-2.3)
rs4263839 TNFSF15 * 9.4E-04 3.9E-02
0.3 (0.2-0.7) 0.43 (0.19-0.98)
rs10761659 ZNF365 5.5E-03 * 1.4E-03 4.7E-02
1.9 (1.2-3.0) 1.8 (1.3-2.6) 1.53 (1.00-2.34)
rs150550 ZMIZ1 2.2E-02
2.9 (1.1-7.5)
rs11190140 NKX2/3 1.1E-02 1.0E-02 2.6E-02 3.4E-02
0.5 (0.3-0.9) 0.6 (0.4-0.9) 0.5 (0.3-0.9) 0.61 (0.39-0.97)
rs2066844 NOD2 * 1.4E-06 * 2.1E-03 2.4E-02
2.8 (1.8-4.3) 1.9 (1.3-3.0) 1.9 (1.1-3.2)
rs2066845 NOD2 * 1.2E-05 2.7E-02 * 4.3E-09 2.2E-02
3.8 (2.0-7.1) 2.3 (1.1-4.9) 4.9 (2.8-8.9) 2.16 (1.10-4.22)
rs2066847 NOD2 * 6.5E-07 * 3.7E-06 * 7.2E-05 * 2.2E-04
3.7 (2.1-6.4) 3.3 (1.9-5.6) 5.7 (2.2-
15.0)
5.11 (1.98-
13.21)
At least one risk
genotype
NOD2 * 9.6E-15 * 5.0E-11 * 6.2E-06 * 4,2E-04
3.8 (2.7-5.3) 2.9 (2.1-4.1) 2.8 (1.8-4.4) 2.19 (1.41-3.39)
rs713875 MTMR3 2.7E-03 3.1E-02 4.4E-02
1.8 (1.2-2.7) 1.5 (1.0-2.1) 1.7 (1.0-2.8)
rs2413583 MAP3K7IP1 3.4 E-03 2.1E-02
0.2 (0.04-0.6) 0.2 (0.04-
0.9)
doi:10.1371/journal.pone.0168821.t003
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a protective effect towards a CD localized to the ileum. This was the case for carriers of the
minor genotype (aa) for rs2413583 on MAP3K7IP1 locus [P = 0.003, OR 0.2 (0.04–0.6)], and
for those carrying the ‘aa’ genotype of rs7547847 located in the IL23R gene [P = 0.001, OR 0.4
(0.2–0.7)].
Further, we applied a multiple stepwise logistic regression method for all the variations
remaining significantly associated after using the Bonferroni correction for multiple compari-
sons (p<2.6e-3). For the NOD2, the presence of at least 1 variant was taken into account. All
the variations resulted independently associated with ileal localization. In particular, the carri-
ers of at least one of the NOD2 mutations [P = 6.9e-10, OR 3.8 (2.5–5.8)], as well as the carriers
of rs9858542 (BSN) [P = 6.6e-5, OR 2.2 (1.5–3.3)], and rs10000113 (IRGM) [P = 4.7e-4, OR 2.1
(1.4–3.2)] mutations were at risk of developing an ileal disease, while those carried the “aa”
genotype in rs7517847 (IL23R) resulted protected toward developing an ileal involvement
[P = 0.01, OR 0.4 (0.2–0.8)] (data not shown). No evidence for statistical interactions between
one gene to others were observed (P> 0.05).
Colonic localization
When compared to healthy controls, seven (24%) SNPs of 7 loci resulted associated with a
colonic disease (Table 3). The most relevant association was for variations in genes IL23R,
MST1 and for those on the locus 10q21. In particular, the ‘aa’ genotype of the rs7517847
(IL23R) conferred protection [P = 0.005, OR 0.40 (0.2–0.8)], while carriers of the ‘AA’ or ‘Aa’
genotypes of the variations rs10076169 (ZNF365) and rs3197999 (MST1) were at higher risk:
[P = 0.005, OR 1.9 (1.2–3.0)] and [P = 0.007, OR 1.9 (1.1–2.4)], respectively. After applying the
Bonferroni correction, all prior associations were nullified.
Ileo-colon localization
For this disease site, 14 SNPs (48%), all belonging to 9 loci, emerged as significantly associated
(Table 3). The polymorphisms of the NOD2 showed the highest association: rs2066844 [P =
0.002, OR 1.9 (1.3–3.0)], rs2066845 [P = 4.3e-9, OR 5.0 (2.8–8.9)] and rs2066847 [P = 3.7e-6,
OR 3.3 (1.9–5.6)]. Carriers of at least one of the previous mutations were at risk for the ileoco-
lonic disease [P = 5.0e-11, OR 2.9 (2.1–4.1)]. The two variations in the IRGM gene were both
associated to ileocolonic localization namely the rs1000113 [P = 2.3e-6, OR 2.2 (1.6–3.1)], and
the rs4958847 [P = 0.001, OR 1.7 (1.2–2.3)]. The SNP rs10761659 of the ZNF365 gene was also
associated with this CD site [P = 0.001, OR 1.6 (1.1–2.3)].
A protective effect toward a CD located simultaneously to the colon and the ileum was
afforded by two SNPs of the IL23R gene, namely rs11209026 [P = 0.003, OR 0.5 (0.3–0.8)] and
rs7517847 [P = 0.005, OR 0.5 (0.3–0.8)]; the SNP rs4263839 of the TNFSF15 gene was also asso-
ciated with this disease site [P = 0.001, OR 0.3 (0.2–0.7)]. At multiple stepwise logistic regression
analysis, all the variations, at exception of the rs4958847 in the IRGM gene, were independent
predictors of an ileocolonic localization. In particular, carriers of at least one NOD2 mutations
[P = 2.1e-7, OR 2.9 (1.9–4.3)], were at risk for the colonic disease, as well as the carriers of muta-
tions in rs10761659 (ZNF365) [P = 6.6e-4, OR 2.1 (1.4–3.1)] and those in rs10000113 (IRGM)
[P = 2.8e-4, OR 2.0 (1.4–3.0)]. Carriers of the “aa” genotype in rs4263839 (TNFSF15) resulted
protected to develop a ileocolonic disease [P = 0.04, OR 0.4 (0.2–0.9)] (data not shown). No evi-
dence for statistical interaction between these genes was observed (P>0.05).
Ileum vs colonic localization
By comparing the ileal to the colonic CD, 5 out of 29 SNPs (17%), belonging to 4 loci, were dif-
ferentially expressed (P< 0.05) (Table 3). In particular, the significant association was shown
Crohn’s Disease Sites and Genetic Variants
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in patients carrying the NOD2 risk genotypes ‘aa’ + ‘Aa’ at either the rs2066844 [P = 0.02, OR
1.9 (1.1–3.2)] or the rs2066847 [P = 7.2e-5, OR 5.8 (2.2–15.0)] and in those with at least one of
the 3 NOD2 markers [P = 6.2e-6, OR 2.8 (1.8–4.4)]. In contrast, the ‘aa’ genotype for rs2413583
(MAP3K7IP1) was proctective for the ileal localization [P = 0.02, OR 0.2 (0.04–0.9)].
Ileocolon vs colonic localization
By comparing the two disease sites, 3 SNPs (10%) emerged as significantly associated (Table 3),
with SNP rs2066847of the NOD2 gene revealing the highest association [P = 2.2e-4, OR 5.1
(2.0–13.2)]. Carriers of at least one of the 3 NOD2 mutations were at risk for the ileocolonic dis-
ease [P = 4.2e-6, OR 2.2 (1.4–3.4)]. In addition, SNP rs4263839 of the TNFSF15 confers protec-
tion for an ileocolon localizzation [P = 0.04, OR 0.43 (0.2–1.0)].
Ileocolon vs ileal localization
Only 2 (7%) variations were statistically different between ileocolonic and ileal localizations:
SNP rs10761659 of the ZNF365 gene conferred an increased risk [P = 0.047, OR 1.5 (1.0–2.3)],
and the variation rs11190140 of the NKX2/3 [P = 0.04, OR 0.6 (0.1–1.0)] showing a protective
effect for the ileocolonic localization (Table 3). Either in NOD2 positive and negative patients,
the frequency of smokers and non-smokers was weakly significant (P = 0.067) (data not shown).
Cumulative genetic risk score
We aggregated the information from the 23 genetic variants associated to CD and combined the
contribution of each nucleotide polymorphism into a genetic risk score (GRS) (Fig 1). In the
whole CD cohort, the Area Under the Curve (AUC) was 0.70, using a cut off value of 5.5 alleles
(P = 8.6e-20; sensitivity = 0.83; specificity = 0.46). By analyzing each Crohn’s disease location
versus healthy controls, the AUC increased in patients with ileal (AUC = 0.73; P = 5.4e-13; sensi-
tivity = 0.85; specificity = 0.46) and ileocolonic localization (AUC = 0.72; P = 3.2e-14; sensitiv-
ity = 0.83; specificity = 0.46); in patients with pure colon localization an AUC of 0.66 was found
(P = 1.4e-6; sensitivity = 0.80; specificity = 0.46). Next we considered the differentiating ability
between an ileal or a colonic disease after combining the 23 genetic markers significantly associ-
ated to CD in the present investigation. The resulting GRS performed poorly in differentiating
colonic versus ileal disease: AUC = 0.58; P = 0.03. Improved results became evident when we con-
sidered in the analysis only the NOD2 (rs2066844 and rs2066847), NKX2/3, MAP3K7IP1 and
MTMR3 SNPs: AUC = 0.60; P = 2.7e-3; sensitivity = 0.52; specificity = 0.65 (data not shown).
Discussion
Genome-wide association studies, Immunochip and meta-analyses identified in patients with CD
different susceptibility loci and possible candidate genes, that might affect the predisposition to
the disease. Most involved genes were related to the innate and adaptive immunity, bacterial rec-
ognition, and autophagy-related mechanism. Cumulative evidences support the concept that defi-
ciencies of innate immune cell functions, principally due to the three major mutations in the
NOD2 gene, represent a crucial key in CD and may help distinguish it from UC [15, 19].On the
other side, serological and fecal biomarkers, although have the potential to become cornerstones
of predictive models for monitoring the course of IBD, have been inconsistent in distinguishing
either patients with CD or UC or in determining the different intestinal location of CD [20].
Very recently, a large genotype-phenotype study, carried out by the International IBD
Genetic Consortium, highlighted that three loci namely 16q12/NOD2, 6p21/MHC and 3p21/
MST1 were of some guide in conditioning the site of CD within the gastrointestinal tract, with
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the 16q12/NOD2 locus as a major determinant of ileal disease, and the 6p21/MHC locus
mainly associated with colonic disease [15].
The aim of the present work was to assess the potential advantage to use a panel of genetic
markers to predict the clinical location in CD patients, and to use this information to stratify
patients for a more effective targeted medical treatment.
In a case control study, we confirmed the association for 23 of the 26 variations associated
to CD and IBD, while none of the HLA markers suggested in the Cleynen [15], resulted signifi-
cantly associated. As expected, the most significant associations were observed for the variants
in NOD2, IL23R, IRGM, TNFSF15 and MAP3K7IP1 genes.
Considering the three NOD2 major variants, the strongest association was achieved in car-
riers of at least one mutation. These figures remained still significant when we sorted the entire
cohort of CD patients by ileal and Ileocolonic disease sites as compared to healthy controls. Car-
riers of at least one risk genotype of the L1007fsX (rs2066847) variant were statistically associated
to ileal localization versus the colonic ones. This variant is also able to discriminate between ileo-
colonic and colonic sites increasing the risk in patients with ileocolonic CD. In accordance with
Cleynen paper [15], NOD2 gene drives the association with both ileal and ileocolonic disease
location, and L1007fsX variant remained the best marker for both sites. The smoking habits
resulted only weakly associated in the group of NOD2 negative patients with ileal involvement,
although smoking is one of the most replicated risk factors in CD pathogenesis [2].
A significant association was also found for the IRGM gene, that plays a role in the innate
immune response by regulating autophagy in response to intracellular pathogens. Two poly-
morphisms of the IRGM gene were associated with CD risk in the study by the Wellcome
Trust Case–Control Consortium GWA [21]. In addition, in a previous study we found these
Fig 1. Receiver Operating Characteristic curve (ROC) for allele count and weighted genetic risk score
(GRS) based on 23 SNPs used to measure the area under the curve (AUC) in ileal Crohn’s disease, colonic
Crohn’s disease and ileocolonic Crohn’s disease patients compared to healthy controls, and in ileal
Crohn’s disease compared to colonic Crohn’s disease patients.
doi:10.1371/journal.pone.0168821.g001
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polymorphisms significantly associated with an aggressive behavior of CD [22]. In the present
investigation, we confirmed the data for the two variations of the IRGM gene. In detail, for the
rs1000113 variant of this gene we found a strong association with the ileal and ileocolon locali-
zation. Moreover, for the rs4958847 variant the association power was even higher in patients
with ileocolonic localization. We have to acknowledge that after applying the Bonferroni cor-
rection, the significance of these associations waned off.
Of interest, the genes analyzed in this study, namely the TNFSF15 and MAP3K7IP1,
proved to have a protective power for the development of CD. The original observation that the
TNFSF15 gene was strongly associated with CD was provided by studying a Japanese cohort of
patients and our Italian cohort [23, 24]. The gene encodes for a protein named TL1A which
exerts a defensive role in the gut against pathogens [25, 26]. We found the rs4263839 variation
of this gene to be associated to CD cohort: carriers of the ‘aa’ genotype appeared to be protected
against the development of the disease at colonic and ileocolonic site, but not at the ileal site. On
the contrary, the rs2413583 SNP of the MAP3K7IP1 gene was protective for an ileal CD. This
variation was associated in CD by Franke et coll. [27]. Our investigation is the first independent
confirmation of the protective power of the marker rs2413583 to development an ileal CD.
In the present investigation we typed 2 SNPs on the locus 3p21 encompassing the genes
BSN and MST1. This locus resulted one of the three loci associated in the genotype-phenotype
study by the International Consortium [15] and influenced the occurrence of extraintestinal
manifestations in CD patients in our previously work [28]. Both markers resulted associated
with CD, although only rs9858542 persisted associated with ileal localization following the
Bonferroni correction; the significance was still maintained at the multiple stepwise logistic
regression analysis. On the contrary, any association with SNPs of the HLA region was
detected in our CD population. These data are in contrast with Cleynen study [15], where
HLA markers prevailed in colonic CD. The numerically small sample size of the present study
may have obscured the HLA impact on colonic CD.
The value of including all information provided by the single associated variants to CD in a
genotype risk score was an essential component of this study even if the emerging results
appear of marginal clinical benefit. Indeed, our genotype risk score, based on 23 single varia-
tions, proved to have a discriminant capacity for the diagnosing CD at a statistically level, even
if the AUC value was only 0.70 (P = 8.6e-20). The AUC value increased minimally when
restricting the analysis to patients with pure ileum (AUC = 0.73; P = 5.4e-13) or ileocolon
(AUC = 0.72; P = 3.2e-14) involvement as compared to the control group, but the AUC value
decreased in those with colonic involvement (AUC = 0.66; P = 1.4e-6), well in keeping with
similar results from previous investigations [29–33].
To date, there are not available genetic markers that can be used to accurately predict the
risk of developing Crohn’s disease. Here we emphasize that the markers, so far identified as
associated with CD, are actually more specifically linked to an ileocolonic and an ileal location
of CD disease, whereas the pure colon CD remains orphan of a substantial genetic support.
In conclusion, although with the paucity of panel of loci analyzed, our findings reaffirm the
existence of at least three different subgroups of CD patients, with a genetic signature distinc-
tive to the three main CD sites. These results might have therapeutic implications in future
work in the event a specific therapeutic target will be proved more effective in specific sites of
the CD in respect to the other one(s).
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